Abstract: Disclosed herein are chimeric antigens, comprising an hepatitis C virus (HCV) antigen and a Fc fragment of an immunoglobulin for eliciting an immune response against said antigen. The immune response is enhanced by presenting the host immune system with an immune response domain (HCV antigen from HCV core, envelope, or non-structural protein fragments) and a target binding domain (an Fc fragment). By virtue of the target binding domain, antigen presenting cells internalize and process the chimeric antigens for antigen presentation, thereby eliciting both a humoral and cellular immune response.
Type:
Application
Filed:
October 13, 2006
Publication date:
September 24, 2009
Applicant:
VIREXX MEDICAL CORP.
Inventors:
Rajan George, Lorne Tyrrell, Antoine A. Noujaim, Bruce Darryl Hirsche, Dakun Wang, Allan Ma, Bruce Motyka
Abstract: The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or AV-malformations or aneurysms or endoleaks; the solid-phase agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the rapid formation of a platelet-mediated thrombus about the solid-phase agent causing vessel occlusion.
Type:
Application
Filed:
October 30, 2007
Publication date:
July 3, 2008
Applicant:
VIREXX MEDICAL CORP.
Inventors:
Michael W. Stewart, Antoine Noujiam, Roland H. Person
Abstract: The present invention relates generally to methods and compositions for targeting, delivering, and activating platelet-dependent vascular occlusion agents. In particular, antibodies carrying platelet binding agents are targeted to hyperplastic cells or tissues, such as the vasculature of solid tumor masses; the platelet binding agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the formation of a platelet-mediated thrombus-causing vessel occlusion.
Type:
Grant
Filed:
August 17, 2005
Date of Patent:
June 24, 2008
Assignee:
ViRexx Medical Corp.
Inventors:
Michael W. Stewart, Antoine Noujaim, Roland H. Person
Abstract: Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular, the compounds and methods elicit immune responses against foreign antigens that are otherwise recognized by the host as “self” antigens, thus breaking host tolerance to those antigens. Presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises an antibody fragment, enhances the immune response against the foreign or tolerated antigen. Antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response against the desired antigen.
Type:
Application
Filed:
August 5, 2004
Publication date:
February 10, 2005
Applicant:
ViRexx Medical Corp.
Inventors:
Rajan George, Lorne Tyrrell, Antoine Noujaim, Dakun Wang, Allan Ma
Abstract: Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular embodiments, the compounds and methods elicit immune responses against antigens that are otherwise recognized by the host as “self” antigens. The immune response is enhanced by presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises a xenotypic antibody fragment. By virtue of the target binding domain, antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response.
Type:
Application
Filed:
August 5, 2004
Publication date:
January 20, 2005
Applicant:
ViRexx Medical Corp.
Inventors:
Rajan George, Lorne Tyrrell, Antoine Noujaim, Dakun Wang, Allan Ma